FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

62 letters match. Newest first.

  1. Daniel Fred Goodman, M.D./Goodman Eye Center

    FDA warns Dr. Daniel Fred Goodman/Goodman Eye Center over clinical drug study without required FDA application and missing consent/assent.

    High risk
  2. Smitha C. Reddy, M.D./ACRC Studies, LLC

    FDA warns Dr. Smitha Reddy over clinical trial protocol violations, including wrong drug given and broken blinding.

    High risk
  3. "Daniel C. Tarquinio, D.O./Center for Rare Neurological Diseases

    FDA warns clinical investigator Daniel C. Tarquinio over enrolling ineligible subjects in investigational drug trials.

    High risk
  4. Sabine S. Hazan, M.D.

    FDA warned Dr. Sabine Hazan that she enrolled and gave investigational drugs to subjects while IRB (ethics board) approval had lapsed.

    High risk
  5. CytoDyn, Inc.

    FDA warns CytoDyn over video promoting unapproved leronlimab as safe and effective for COVID-19.

    High risk
  6. Richard J. Obiso, PhD dba Avila Herbals, LLC

    FDA warns Avila Herbals and investigator over drug trial lacking required FDA application, ethics review, and consent.

    High risk
  7. Vasyl Melnyk, M.D.

    FDA warns Dr. Vasyl Melnyk that he lost required records for an investigational drug trial.

    Medium
  8. Joseph A. Zadra, M.D.

    FDA warned clinical investigator Dr. Zadra for enrolling an ineligible subject and skipping required safety labs in a drug study.

    High risk
  9. RAAS Nutritionals, LLC/Rare Antibody Antigen Supply, Inc.

    FDA says RAAS Nutritionals ran human drug studies without required IND applications, despite claiming products were dietary supplements.

    High risk
  10. Kaleido Biosciences, Inc.

    Kaleido Biosciences ran COVID-19 clinical trials of KB109 without required IND, FDA says.

    High risk
  11. Evelyn Lopez-Brignoni, M.D.

    FDA warns Dr. Evelyn Lopez-Brignoni over inadequate dosing in pediatric investigational drug trials.

    High risk
  12. Ignacio J. Rodriguez, MD

    FDA warns Dr. Ignacio J. Rodriguez for enrolling ineligible subjects and giving study drug without required checks in a clinical trial.

    High risk